Background
The bone health of patients with locally advanced and metastatic prostate cancer is at risk both from treatment-related loss of bone density and skeletal-related events from metastasis to bones. Evidence-based guidelines recommend the use of denosumab or zoledronic acid at bone metastasis-indicated dosages in the setting of castration-resistant prostate cancer with bone metastases, and at the osteoporosis-indicated dosages in the hormone-sensitive setting in patients with a significant risk of fragility fracture. For the concerns of jaw osteonecrosis, a dental evaluation is recommended before starting bone modifying agents. The literature review suggests that there is a limited evidence-based practice for bone health with prostate cancer in the real world. Both underdosing and overdosing on bone remodeling therapies place additional risk on bone health. An incomplete dental workup before starting bone modifying agents increases the risk of osteonecrosis of the jaw.
Methods
To minimize the deviation from evidencebased guidelines at VA Salt Lake City Health Care, and to provide appropriate bone health care to our patients, we created an algorithm-based clinical practice tool. This order set was incorporated into the electronic medical record system to be used while ordering a bone remodeling agent for prostate cancer. The tool prompts the clinicians to follow the appropriate algorithm in a stepwise manner to ensure a pretreatment dental evaluation and use of the correct dosage of drugs.
Results
We analyzed the data from Sept 2019 to April 2022 following the incorporation of this tool. 0/35 (0%) patients were placed on inappropriate bone modifying agent dosing and dental health was addressed on every patient before initiating treatment. We noted a significant change in the clinician’s practice while prescribing denosumab/zoledronate before and after implementation of this tool (24/41 vs 0/35, P < .00001); and an improvement in pretreatment dental checkups before and after implementation of the tool was noted to be 12/41 vs 0/35 ( P < .00001).
Conclusions
We found that incorporating an evidence-based algorithm in the order set while prescribing bone remodeling agents led to a significant improvement in our institutional clinical practice to provide high-quality evidence-based care to our patients with prostate cancer.
